- The US FDA approved mFlusiva for people aged 50 and over on 5 August.
- In the pivotal trial, protocol-defined, laboratory-confirmed illness occurred in about 2.0% of one group and 2.8% of the other.
- For adults aged 65 and over, the FDA requires a further study against a high-dose influenza vaccine.
Inside this story 2 perspectives
Two people can both receive a seasonal influenza vaccine and still be in different groups in a clinical trial. That detail matters to a figure in the news this week. The United States Food and Drug Administration approved Moderna’s mFlusiva on 5 August for people aged 50 and older. A study reported relative vaccine efficacy of 26.6%. The researchers arrived at that figure by comparing the new vaccine with a licensed standard-dose flu vaccine.
The trial, published in the New England Journal of Medicine, assigned participants at random. It used a double-blind design and more than 40,000 adults received one of the two vaccines. Investigators looked for an illness meeting a specified set of criteria and confirmed by a laboratory test. That combination gave them a consistent way of counting a case in either group.
Reading the result from the case counts
Among participants in the efficacy analysis, 411 of 20,179 in the mRNA group developed the specified illness. The standard-dose group recorded 557 cases among 20,124 people. Rounded, those proportions are 2.0% and 2.8%. For a reader picturing 1,000 people, the observed rates work out to roughly 20 cases in one group and 28 in the other during this study.
The observed absolute difference is about eight cases per 1,000. The relative result expresses the difference against the risk in the comparison group. Its estimate carries uncertainty. The study reported a 95% confidence interval ranging from 16.7% to 35.4% for relative efficacy. The number of cases averted in another season could differ because it also depends on how often the circulating virus causes the illness being measured.
Participants reported some short-lived reactions more frequently after the mRNA vaccine. For instance, about two-thirds of that group reported pain at the injection site, compared with about three in ten in the standard-dose group. The researchers described most of the reactions they solicited as mild or moderate and temporary.
A different comparison for older adults
The FDA issued a traditional approval for people aged 50 to 64. The indication for adults aged 65 and over received accelerated approval. For that group, the regulator requires a further randomised study comparing the new product with a high-dose flu vaccine. It wants evidence of clinical benefit under that comparison. Findings about antibody responses and findings about cases of illness answer different questions.
For someone following the news outside the United States, the decision identifies the population and evidence accepted by one regulator. Availability, seasonal recommendations and procurement are local matters. Three details travel reliably with the story wherever it is read: who took part, what each group received and which illness the researchers actually counted.



